Who Owns Zydus Lifesciences?
Ownership snapshot for Jun 2026
Unlock Full Ownership Intelligence
Go beyond a snapshot — track 12 quarters of shareholding trends, insider trading activity, and AI-powered signals.
- 12 quarters of shareholding trend data
- Insider trading & bulk deal analysis
- AI-powered shareholding insights & signals
Billed annually
Understanding Shareholding Categories
Promoter (Non-Pledged): Founders & holding companies. High holding (>50%) shows alignment with shareholders.
Promoter (Pledged): Shares used as loan collateral. Forced selling risk if loans default.
DII: Mutual funds, insurance & pension funds. Rising DII stake signals domestic confidence.
FII: Foreign portfolio investors & hedge funds. High FII stake shows global interest.
Government: Central/state govt & PSU holdings.
Public & Others: Retail investors, HNIs, NRIs & corporates.
Data from audited consolidated filings. For educational purposes only — not investment advice. Last update: Jun 2026
Related Stocks
AstraZenca Pharma (ASTRAZEN)
Revenue grew 32.1% to ₹1,757 Cr in FY2025.
Jenburkt Pharma (JENBURKT)
Revenue of ₹152 Cr in FY2025.
Gufic Biosciences (GUFICBIO)
Revenue compounded at 18.4% annually over 10 years.
Abbott India (ABBOTINDIA)
Revenue of ₹6,409 Cr in FY2025.
Sun Pharma (SUNPHARMA)
Revenue of ₹60,434 Cr in FY2026.
Anuh Pharma (ANUHPHR)
Revenue of ₹662 Cr in FY2025.